|
|||||
|
|
Association between complete response and outcomes in transplant‐eligible myeloma patients in the era of novel agents |
|
| Authors: | Helgi van de Velde Anil Londhe Ozlem Ataman Helen L Johns Stephen Hill Emma Landers Jesse A Berlin |
| Affiliation: | 1. Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAFormerly Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium;2. Janssen Research and Development, Horsham, PA, USA;3. Janssen Research & Development, High Wycombe, UK;4. FireKite, an Ashfield Company, part of UDG Healthcare plc, Maidenhead, UK;5. Johnson & Johnson, Titusville, NJ, USA |
| Abstract: | |
| Keywords: | multiple myeloma treatment outcome meta‐analysis progression‐free survival overall survival complete response bortezomib lenalidomide thalidomide |
